Management of C. difficile Infection

Rationale for Avoiding Prochlorperazine

Prochlorperazine has antimotility effects that can lead to prolonged retention of C. difficile toxins in the colon, potentially worsening the infection and increasing the risk of complications 1, 3
Masking diarrhea symptoms with anti-motility agents like prochlorperazine can delay appropriate diagnosis and treatment of C. difficile infection 1, 2
Symptom suppression may create a false impression of clinical improvement while allowing the underlying infection to progress 2, 3

For mild-moderate C. difficile infection: Oral vancomycin 125 mg four times daily for 10 days is now preferred over metronidazole 3, 4
For severe C. difficile infection: Oral vancomycin 125 mg four times daily or fidaxomicin 200 mg twice daily for 10 days 3, 4
For patients who cannot take oral medications: Vancomycin may be administered as a retention enema via a rectal tube 3

Diarrhea is a key clinical symptom for monitoring treatment response in C. difficile infection; suppressing this symptom with prochlorperazine can make it difficult to assess clinical improvement 1, 2
Severe C. difficile infection can progress to toxic megacolon, sepsis, or death if not properly managed 3
Antimotility agents like prochlorperazine have been associated with prolonged symptoms and increased complications in infectious diarrhea 1, 2
For patients with legitimate antiemetic needs, consider alternative agents with less impact on gut motility after discussing with infectious disease specialists 3, 5

In patients with inflammatory bowel disease and C. difficile, antimotility agents pose an even greater risk due to the already compromised colonic function 6
Immunocompromised patients are at higher risk for severe C. difficile infection and should especially avoid medications that may mask symptoms or worsen disease 6